Ishita Gambhir, MD
Neurology · Washington, DCNPI 1548427719
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 64.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $4,740 and has fallen 83.0% since, to $806 in 2025.
Across 149 payments — averaging $50.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Acadia Pharmaceuticals Inc$391
- Merz Pharmaceuticals, LLC$331
- MDD US Operations, LLC$305
- GE HealthCare$290
- Amneal Pharmaceuticals LLC$218
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$2,62535%
- Travel & lodging$1,26017%
- Food & beverage$3,53347%
- Education$421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $4,801 |
| Acadia Pharmaceuticals Inc | 20 | $391 |
| Merz Pharmaceuticals, LLC | 7 | $331 |
| MDD US Operations, LLC | 8 | $305 |
| GE HealthCare | 10 | $290 |
| Amneal Pharmaceuticals LLC | 11 | $218 |
| Medtronic | 3 | $192 |
| Organogenesis Inc. | 1 | $122 |
| Supernus Pharmaceuticals, Inc. | 1 | $96 |
| Avion Pharmaceuticals | 4 | $81 |
| Abbott | 4 | $75 |
| Adamas Pharmaceuticals, Inc. | 4 | $69 |
| Amgen | 2 | $65 |
| Ipsen Biopharmaceuticals, Inc | 3 | $60 |
| Avanir Pharmaceuticals, Inc. | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Lilly USA, LLC | 2 | $38 |
| Acorda Therapeutics, Inc | 2 | $37 |
| Lundbeck LLC | 2 | $34 |
| UCB, Inc. | 1 | $21 |
| Corium, LLC | 1 | $21 |
| Biogen | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Promius Pharma LLC | 1 | $14 |
| EMD Serono, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Duopa$3,835
- PERCEPT PC BRAINSENSE$104
How this compares
$7,460 in reported general payments places this provider in the 70th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 46 | $81,203 |
| NourianzIstradefylline | 13 | $54,112 |
| Rasagiline Mesylate | 41 | $8,999 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 265 | $8,134 |
| Rivastigmine | 11 | $3,775 |
| Entacapone | 22 | $3,727 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 15 | $2,788 |
| Memantine Hcl | 20 | $2,366 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 19 | $2,120 |
| AmantadineAmantadine Hcl | 16 | $1,686 |
| Propranolol Hcl ErPropranolol Hcl | 17 | $1,498 |
| Ropinirole ErRopinirole Hcl | 11 | $1,336 |
| Donepezil Hcl | 57 | $1,256 |
| Trihexyphenidyl Hcl | 11 | $248 |
| Propranolol Hcl | 15 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $218 | $81,20346 claims |
| Kyowa Kirin, Inc.Nourianz | $45 | $54,11213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 113 neurology providers in District of Columbia.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.